In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous stents, the target lesion revascularisation rate was 3.8% and the rate of definite stent thrombosis was 1.4%. In addition, the rate of cardiac death was 2.9% (four patients), and the target vessel revascularisation was 5.8%.
“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous stent’s ability to accelerate endothelialisation may reduce the risk of stent thrombosis. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”
In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8% of patients were male. Notably, 20.1% of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.